CACLP 2026 | Driven by Innovation, Founded on Quality — Accelerating Excellence in Domestic Coagulation Testing

From March 21–23, 2026, the 23rd China Association of Clinical Laboratory Practice (CACLP) Expo was held at the Xiamen International Expo Center. This year’s conference, themed "Moving Towards Innovation, Achieving Excellence Through Quality," focused on technology-driven innovation and the high-quality development of the In-Vitro Diagnostics (IVD) industry. Shanghai Sun Biotech participated with its full range of coagulation testing solutions, showcasing significant achievements in technical innovation and the construction of its comprehensive product ecosystem.

Moving Towards Innovation: Driving Continuous Upgrades in Coagulation Diagnostic Capabilities

The core of "Moving Towards Innovation" lies in addressing clinical needs through continuous technological breakthroughs. On the morning of March 21, Shanghai Sun Biotech held a product launch for the UG1200 Fully Automated Coagulation Analyzer. Built upon the UG series' optical-magnetic hybrid detection platform and integrated with platelet aggregation assessment, this device further extends high-end coagulation diagnostic capabilities to small and medium-sized laboratories.

Supported by sustained R&D investment, the company has consistently unveiled innovative results at CACLP over the past five years, steadily refining its coagulation product portfolio. To date, the company has established a diverse lineup, including:

• UP Series: Delivering high stability and cost-effectiveness.

• UR Series:      Designed for ultra-high-speed testing.

• UG Series:      Optical-magnetic hybrid analyzers with integrated aggregation functions.

• UL-2000LAS:      A laboratory automation system.

  
  

This comprehensive range achieves full coverage, from primary care facilities to large-scale medical centers. Providing more healthcare institutions with access to high-quality coagulation testing is both the starting point and the ultimate goal of Shanghai Sun Biotech’s ongoing innovation.

Achieving Excellence Through Quality: Clinical Evidence Fostering Trusted Quality

While innovation expands boundaries, quality solidifies the foundation. To meet the diagnostic and treatment demands of hemostasis and thrombosis, Shanghai Sun Biotech has established a complete menu of specialized reagents. This includes coagulation factors (II, V, VII, VIII, IX, X, XI, XII), Protein C, Protein S, Antithrombin III (AT-III), Lupus Anticoagulant (LA), and Anti-Xa activity assays, covering critical clinical stages such as screening, diagnosis, and anticoagulant monitoring for bleeding and thrombotic disorders.Beyond expanding its test menu, the company prioritizes clinical validation and quality control. All relevant reagent products have undergone validation through multi-center clinical studies at several major Class A tertiary hospitals across China, utilizing real-world clinical data to ensure the accuracy and stability of test results. Furthermore, the company’s coagulation products have maintained high scores in the National External Quality Assessment (EQA) for 17 consecutive years. This long-term, stable, high-quality performance reflects the company's deep expertise in quality system management and provides a reliable guarantee for clinical applications.

"Moving Towards Innovation, Achieving Excellence Through Quality" represents a pivotal direction for the Chinese IVD industry as it transitions toward high-quality development. Drawing on 25 years of specialized expertise in the coagulation field, Shanghai Sun Biotech will continue to utilize innovation as its engine and quality as its cornerstone. By collaborating with clinical and industry partners, the company remains dedicated to enhancing the level of coagulation diagnosis and treatment in China, contributing professional strength to the implementation of the "Healthy China" strategy.